Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: Inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells

Biochemical and Biophysical Research Communications

Volumn 276, Issue 1, 2000, Pages 371-378

  Jiang, Cheng ^a   Agarwal, Rajesh ^a   Lü, Junxuan ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Angiogenesis switch; HUVEC; In vitro capillary differentiation; MMP 2 gelatinase A; Silymarin; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIOXIDANT; FLAVANOID; SILYMARIN; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BREAST CANCER; CANCER PREVENTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR BLOOD FLOW;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0034675269     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2000.3474     Document Type: Article

References (53)

1. Tumor angiogenesis: Therapeutic implications
2. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
3. Angiogenesis and tumor metastasis
4. Cell and environment interactions in tumor microregions: The multicell spheroid model
5. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
6. Cancer chemoprevention: Principles and prospects
7. Antioxidants and multistage carcinogenesis in mouse skin
8. Natural antioxidants in chemoprevention
9. Skin cancer chemoprevention
10. Studies on the pharmacodynamics, including site and mode of action, of silymarin: The antihepatotoxic principle from Silybum mar. (L) Gaertn
11. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver
12. Inhibition of transformation in cultured rat tracheal epithelial cells by potential chemopreventive agents
13. Evaluation of potential chemopreventive agents using a mouse epidermal cell line, JB6
14. Characterization of effective chemopreventive agents in mammary gland in vitro using an initiation-promotion protocol
15. Protective effects of silymarin against photocarcinogenesis in mouse skin model
16. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in SENCAR mouse skin tumorigenesis model
17. Inhibitory effect of a flavonoid antioxidant silymarin on benzoyl peroxide-induced tumor promotion, oxidative stress and inflammatory responses in SENCAR mouse skin
18. Inhibitory effect of silymarin, an anti-hepatotoxic flavonoid, on 12-O-tetradecanoylphorbol-13-acetate-induced epidermal ornithine decarboxylase activity and mRNA in SENCAR mice
19. Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: Inhibition of mRNA expression of an endogenous tumor promoter TNFa
20. Anti-carcinogenic effect of a flavonoid antioxidant silymarin in human breast cancer cells MDA-MB 468: Induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of CDKs and associated cyclins
21. A flavonoid antioxidant silymarin inhibits activation of erbB1 signaling, and induces cyclin-dependent kinase inhibitors, G1 arrest and anti-carcinogenic effects in human prostate carcinoma DU145 cells
22. Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression
23. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: Implications for prostate cancer intervention
24. Modulation of mitogen-activated protein kinase activation and cell cycle regulators by the potent skin cancer preventive agent silymarin
25. Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake
26. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin
27. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures
28. Matrix metalloproteinases and the development of cancer
29. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
30. Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2
31. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins
32. Vascular endothelial growth factor is a secreted angiogenic mitogen
33. Vascular permeability factor, an endothelial cell mitogen related to PDGF
34. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
35. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
36. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells
37. Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor
38. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy
39. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo
40. VEGF deprivation-induced apoptosis is a component of programmed capillary regression
41. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
42. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal
43. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma
44. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast
45. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms
46. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer
47. Tumor induction of VEGF promoter activity in stromal cells
48. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
49. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells
50. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression
51. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways
52. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
53. Activator-protein-1 binding potentiates the hypoxia-inducible factor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells